Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
British Journal of Haematology|February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL studyElena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Cancer|May 19, 2023
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20)Simone Oerlemans, Fabio Efficace, Charalampia Kyriakou, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Oncotarget|November 21, 2017
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemiaSara Galimberti, Cristina Bucelli, Elena Arrigoni, et al.
Frontiers in Oncology|June 15, 2018
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free RemissionMonica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Cancer|April 1, 2021
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcomeFrancesca Palandri, Mario Tiribelli, Massimo Breccia, et al.
Pageof 15